 | |
| Clinical data | |
|---|---|
| Other names | (10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H29GdN4O7 |
| Molar mass | 558.69 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Gadoteridol (INN) is agadolinium-based MRI contrast agent, used particularly in the imaging of thecentral nervous system. It is sold under the brand nameProHance.[3] Gadoteridol was first approved for use in the United States in 1992.[4]
Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.
 | This article aboutmagnetic resonance imaging is astub. You can help Wikipedia byexpanding it. |
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
